InSite Vision to Present at the 8th Annual JMP Securities Healthcare
JMP Securities Healthcare Conference 2013
ALAMEDA, Calif. -- July 2, 2013
InSite Vision Incorporated (OTCBB: INSV) today announced that Timothy Ruane,
InSite’s Chief Executive Officer, will be presenting at the 8^th Annual JMP
Securities Healthcare Conference on Tuesday, July 9, 2013, at 12:00 pm ET at
the St. Regis Hotel in New York City, NY.
A webcast of the presentation will be available on the investor section of
InSite Vision’s website at www.insitevision.com and will be available for 30
days following the event.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care
needs based on its innovative DuraSite^® platform technologies. The DuraSite
and DuraSite 2 drug delivery systems extend the duration of drug retention on
the surface of the eye, thereby reducing the frequency of treatment and
improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for
the treatment of bacterial eye infections, AzaSite^® (azithromycin ophthalmic
solution) 1%, marketed in the U.S. by Merck, and Besivance^® (besifloxacin
ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is
advancing three novel ophthalmic therapeutics through Phase 3 clinical
studies: AzaSite Plus^™ and DexaSite^™ for the treatment of eye infections,
and BromSite^™ for pain and inflammation associated with ocular surgery. For
further information on InSite Vision, please visit www.insitevision.com.
AzaSite^®, DuraSite^® and DuraSite^® 2 are registered trademarks of InSite
Vision Incorporated. AzaSite Plus^™, BromSite^™, and DexaSite^™ are trademarks
of InSite Vision Incorporated.
BESIVANCE^® is a registered trademark of Bausch + Lomb Incorporated.
Louis Drapeau, 510-747-1220
Chief Financial Officer
Media and Investor inquiries:
Michelle Corral, 415-794-8668
Karen L. Bergman, 650-575-1509
Press spacebar to pause and continue. Press esc to stop.